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Aims To test the prognostic value of emerging biomarkers in the Reduction of Events by Darbepoetin Alfa in Heart Failure
(RED-HF) trial.
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Methods
and results
Circulating cardiac [N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity troponin T
(hsTnT)], neurohumoral [mid-regional pro-adrenomedullin (MR-proADM) and copeptin], renal (cystatin C), and
inflammatory [high-sensitivity C-reactive protein (hsCRP)] biomarkers were measured at randomization in 1853
participants with complete data. The relationship between these biomarkers and the primary composite endpoint of
heart failure hospitalization or cardiovascular death over 28months of follow-up (n= 834) was evaluated using Cox
proportional hazards regression, the c-statistic and the net reclassification index (NRI). After adjustment, the hazard
ratio (HR) for the composite outcome in the top tertile of the distribution compared to the lowest tertile for each
biomarker was: NT-proBNP 3.96 (95% CI 3.16–4.98), hsTnT 3.09 (95% CI 2.47–3.88), MR-proADM 2.28 (95%
CI 1.83–2.84), copeptin 1.66 (95% CI 1.35–2.04), cystatin C 1.92 (95% CI 1.55–2.37), and hsCRP 1.51 (95% CI
1.27–1.80). A basic clinical prediction model was improved on addition of each biomarker individually, most strongly
by NT-proBNP (NRI +62.3%, P< 0.001), but thereafter was only improved marginally by addition of hsTnT (NRI
+33.1%, P= 0.004). Further addition of biomarkers did not improve discrimination further. Findings were similar for
all-cause mortality.
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Conclusion Once NT-proBNP is included, only hsTnT moderately further improved risk stratification in this group of chronic
heart failure with reduced ejection fraction patients with moderate anaemia. NT-proBNP and hsTnT far outperform
other emerging biomarkers in prediction of adverse outcome.
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Introduction
B-type natriuretic peptide, produced by the myocardium primar-
ily in response to volume overload and increase in wall stress,
and its inactive metabolite N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP), are established prognostic markers in patients
with heart failure and reduced ejection fraction (HFrEF).1 Simi-
larly, elevated levels of cardiac troponins reflecting cardiomyocyte
necrosis, consistently relate to worse clinical outcomes in both
acute2,3 and chronic4–8 HFrEF patients. Both these biomarkers
may provide additive prognostic information to routinely collected
demographic, clinical and laboratory data in patients with chronic
heart failure (HF).5–7
The relative or incremental predictive role of other emerging
biomarkers related to cardiac function, renal function, neurohor-
monal activation and inflammation, either individually or as part of
a multimarker approach, in HFrEF is less certain. Several poten-
tial candidates for inclusion in a multimarker approach, thought
to be of pathophysiological importance in HF have been identi-
fied. The 52-amino-acid peptide adrenomedullin is a long-acting
vasodilator produced by many tissues including cardiovascular sys-
tem and is increased in HF. Adrenomedullin is unstable in blood
and difficult to monitor, whereas its mid-regional pro-peptide
[mid-regional pro-adrenomedullin (MR-proADM)] is stable, easy
to measure and has been found to predict outcome in acute
and chronic HF patients.9–11 C-terminal pro-arginine vasopressin
(AVP), more commonly known as copeptin, is a stable precur-
sor of AVP, a circulating peptide vasoconstrictor, which is also
involved in water homeostasis.12 Plasma copeptin concentrations
have also been shown, albeit variably, to add incremental prognos-
tic information to both NT-proBNP and high-sensitivity troponin
T (hsTnT) in the acute and chronic setting.13–18 In addition to
cardiac biomarkers, renal function is also an established and pow-
erful predictor of outcomes in HFrEF.1 Although most commonly
evaluated by estimation of glomerular filtration rate (eGFR) using
several creatinine-based formulae, the low-molecular-weight pep-
tide cystatin C may be a more precise measure of renal function in
particular patient groups. In acute and chronic HF, cystatin C has
been reported to be a better predictor of adverse outcomes than
creatinine-based eGFR, and to add incremental prognostic informa-
tion to both NT-proBNP and hsTnT.19–23 Finally, whereas inflam-
mation has been implicated in the pathogenesisis of HF, the relative
value of high-sensitivity C-reactive protein (hsCRP), a reliable and
stable marker of systemic inflammation, as a prognostic marker in
patients with HFrEF is uncertain.7,24–26 The main questions about
emerging biomarkers in HF prognostication are: (i) how do they
perform as prognostic markers compared to B-type natriuretic
peptides, troponin or both (i.e. could we find a better replacement
for one or both of these effective prognostic markers?), or (ii) do
they individually or collectively add further meaningful prognostic
information to the routinely collected variables including a B-type
natriuretic peptide and a troponin? Few studies have addressed
these questions for the emerging biomarkers used either alone or
in a multiple biomarker panel.
Therefore, the primary aim of this study was to assess
the prognostic value of several promising emerging cardiac, ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. neurohormonal, renal and inflammatory biomarkers beyond that
provided by NT-proBNP, troponin, and hsTnT individually and in
combination, in patients enrolled in the Reduction of Events by
Darbepoetin Alfa in Heart Failure (RED-HF) trial.
Methods
Study design and patient selection
RED-HF was a randomized placebo-controlled double-blind trial
designed to test the effect of treatment with darbepoetin alfa, targeting
a haemoglobin of 13.0 g/dL, on clinical outcomes in patients with HFrEF
and anaemia.27,28 Participating patients had to be ≥18 years, New York
Heart Association (NYHA) class II–IV (NYHA class II patients had to
have an unplanned hospital admission or emergency room visit for a
cardiovascular reason within 12months prior to randomization), left
ventricular ejection fraction (LVEF) ≤40% with HFrEF diagnosed for
≥3months, had haemoglobin in the range of 90–120 g/L, and receiv-
ing stable optimal HF therapy. Exclusion criteria included transferrin
saturation<15%, evidence of bleeding or other correctable causes
of anaemia, creatinine >265𝜇mol/L (>3.0mg/dL), and uncontrolled
hypertension (>160/100mmHg). The study randomized 2278 patients
to either darbepoetin alfa (n= 1136) or placebo (n=1142) at 453
sites in 33 countries between June 2006 and May 2012 with a median
follow-up of 28months. The three regions with largest enrolment
were North America (n= 644), Western Europe (n= 609), and Cen-
tral/Eastern Europe (n= 454). The ethics committee at each study cen-
tre approved the trial design, and patients provided written informed
consent, including storage of blood samples for future biomarker
analysis.
Outcomes
The primary outcome for the RED-HF trial was the composite of
death from any cause or first hospitalization for worsening HF. The
pre-specified outcomes investigated in the present post-hoc analysis
were (i) the composite cardiovascular death outcome of first hospi-
talization for worsening HF or death from cardiovascular causes, and
(ii) all-cause mortality. The focus on cause-specific mortality outcome
has been discussed in a recent review.29 Outcomes were adjudicated
according to pre-specified definitions by an independent committee
blinded to treatment assignment.28
Study assessments and biomarker assays
At randomization, fasting venous blood was collected and serum and
plasma were separated and stored at –80 ∘C until thawing for assay.
Serum and plasma samples were shipped on dry ice to a central labo-
ratory (University of Glasgow) for assay of six biomarkers in a single
batch. We did not specifically test frozen stability of the biomark-
ers, but all assays were conducted on first thaw. MR-proADM and
copeptin were measured in plasma and NT-proBNP, hsTnT, cystatin
C, and hsCRP were measured in serum using automated clinical plat-
forms using manufacturer calibrators and controls. MR-proADM and
ultra-sensitive copeptin assays were performed (using a single batch
number) on a Kryptor plus (ThermoFisher Scientific, Hemel Hemp-
stead, UK), assays had limits of detection of 0.05 nmol/L and 0.9 pmol/L,
and had low and high control coefficients of variation of 6.4%, 5.3%
and 6.9%, 11.8%, respectively. NT-proBNP and hsTnT were measured
using an e411 (Roche Diagnostics, Burgess Hill, UK), assays had limits
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
270 P. Welsh et al.
Table 1 Baseline characteristics of RED-HF participants by whether or not a composite cardiovascular death/heart
failure hospitalization occurred during follow-up
Characteristic HF hospitalization or CV death
(n= 1019)
No HF hospitalization or CV death
(n= 1259)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 71.4 (10.9) 68.4 (11.7) <0.001
Male sex 675 (66.2) 659 (52.3) <0.001
Race <0.001
White 765 (75.1) 784 (62.3)
Black 94 (9.2) 108 (8.6)
Other 160 (15.7) 367 (29.1)
BMI, kg/m2 25.9 (23.3–29.7) 26.5 (23.5–30.4) 0.055
Smoking <0.001
Current 52 (5.1) 45 (3.6)
Former 446 (43.8) 401 (31.9)
Never 520 (51.1) 811 (64.5)
Systolic BP, mmHg 117 (19) 122 (17) <0.001
Diastolic BP, mmHg 67.3 (10.9) 71.1 (10.6) <0.001
Diabetes 496 (48.7) 559 (44.4) 0.042
Previous stroke 98 (9.6) 81 (6.4) 0.005
COPD 214 (21.0) 153 (12.2) <0.001
Atrial fibrillation/flutter 431 (42.3) 316 (25.1) <0.001
NYHA class <0.001
II 280 (27.5) 511 (40.6)
III/IV 739 (72.5) 748 (59.4)
LVEF, % 29.2 (7.1) 31.2 (6.5) <0.001
Ischaemic aetiology 793 (77.8) 868 (68.9) <0.001
HF duration, years 4.4 (1.7–8.5) 3.0 (1.1–7.1) <0.001
Heart rate, b.p.m. 72.1 (11.7) 71.8 (10.7) 0.546
Beta-blocker use 854 (83.8) 1083 (86.0) 0.141
ACE-I or ARB use 880 (86.4) 1145 (90.9) <0.001
Creatinine, mg/dL 1.5 (1.2–2.0) 1.2 (1.0–1.6) <0.001
NT-proBNP, ng/L 3067 (1458–6615) 1027 (324–2541) <0.001
Troponin T, ng/L 35.6 (22.2–53.0) 19.1 (11.2–31.9) <0.001
MR-proADM, nmol/L 1.1 (0.8–1.5) 0.8 (0.6–1.1) <0.001
Copeptin, pmol/L 20.3 (9.4–36.0) 11.0 (5.4–22.8) <0.001
Cystatin C, mg/L 1.8 (0.7) 1.4 (0.7) <0.001
CRP, mg/L 3.5 (1.3–8.3) 2.2 (0.9–5.6) <0.001
Values are mean (standard deviation), median (interquartile range), or number (%).
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease;
CRP, C-reactive protein; CV, cardiovascular; HF, heart failure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; MR-proADM,
mid-regional pro-adrenomedullin.
of detection of 5 ng/L (5 pg/mL) and 3 ng/L, respectively, and had low
and high control coefficients of variation (day to day) of 6.4%, 6.2% and
6.5%, 3.7%, respectively. Cystatin C and CRP were measured using a
c311 (Roche Diagnostics), assays had limits of detection of 0.4mg/L
and 0.1mg/L, respectively, and had control coefficients of variation of
2.8% and 3.9%, respectively. Controls for all biomarkers were of a single
lot number for the entire study.
Statistical analysis
Baseline characteristics of participants were tabulated by composite
outcome group using means and standard deviations for continuous
variables, or using median and interquartile range for variables with
skewed distribution, and numbers and percentages for categorical vari-
ables. Comparisons between biomarker concentrations in outcome
groups were made using two tailed t-tests for normally distributed ..
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.. biomarkers, and Wilcoxon rank sum test for non-normally distributed
biomarkers. The relationships among baseline circulating biomarkers
were tested using Spearman correlations, and for other clinical risk fac-
tors trends across tertiles of the biomarker distribution were assessed
using chi-square tests, one-way analysis of variance, or Kruskal–Wallis
rank sum test depending on variable type and distribution.
Kaplan–Meier survival curves were constructed to illustrate
time-to-event outcomes of patients according to tertiles of biomarker
distribution at baseline and compared using the log-rank test. The
associations between baseline levels of biomarkers and outcomes were
evaluated using multivariable Cox proportional hazard models, adjust-
ing for region, age, sex, race, body mass index, smoking, systolic and
diastolic blood pressure, diabetes, chronic obstructive pulmonary dis-
ease, NYHA class, LVEF, time since diagnosis, angiotensin-converting
enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) use,
beta-blocker use, creatinine, HF hospitalization within last 6months,
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Event-free survival experiences of the participants by tertiles of the biomarker distribution corresponding to cut-offs of 947,
3067 ng/L for N-terminal pro-B-type natriuretic peptide (NT-proBNP), 17.9, 36.2 ng/L for high-sensitivity troponin T (hsTnT), 0.73, 1.14 nmol/L
for mid-regional pro-adrenomedullin (MR-proADM), 8.66, 22.99 pmol/L for copeptin, 1.22, 1.84mg/L for cystatin C, and 1.40, 4.94mg/L for
C-reactive protein (CRP). All trends are log-rank P< 0.001. CVD, cardiovascular death.
HF aetiology, stroke, atrial fibrillation/flutter, and heart rate. Diuretics
were used in >90% of participants, and were therefore not included
in the adjustment models. A total of 1853 patients had complete
biomarkers and clinical variable data for analyses. Biomarker utility in
predicting outcome was tested using the fully adjusted model above
as a basic comparator clinical prediction model, to which biomarkers
were then added. Model discrimination was tested using Harrell’s
c-statistic30 and the continuous net reclassification index (NRI),31
adapted for use in survival models.32 For model comparison, c-statistic
and NRI were generated using ordinary non-parametric bootstrapping,
and then P-values obtained from paired t-tests. All statistical analyses
were performed using R version 3.2.3 with additional packages of rms,
pec and survIDINRI.
Results
Baseline characteristics
NT-proBNP, hsTnT, copeptin, MR-proADM, cystatin C and hsCRP
measurements were made at baseline in 1941, 1946, 1873,
1878, 1946, and 1946 patients, respectively. All participants had
detectable NT-proBNP and <1% patients had hsTnT <3 ng/L
(the assay limit of blank). Biomarker and clinical measurements
were complete in 1853 participants. Supplementary material
online, Tables S1–S6 show the baseline characteristics of the ..
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.. patients by tertiles of the biomarker level. Higher biomarker lev-
els were generally associated measures of HF severity including
higher NYHA class, more co-morbidities, older age and greater
impairment of renal function. Supplementary material online, Table
S7 shows associations between the biomarkers and several clinical
variables and amongst themselves. Particularly strong associations
were found between all biomarkers and creatinine. NT-proBNP
was also strongly associated with proADM, copeptin, cystatin C.
Follow-up for incident events
Over the median 28months, 1019 patients experienced one of the
components of the composite outcome of first HF hospitalization
or cardiovascular death and 932 participants died from any cause
(834 composite events and 769 all-cause deaths in those with
complete biomarker data). Those who experienced the composite
outcome during follow-up were older, more likely to be male,
white, and smokers. They were also more likely to have a history
of stroke, chronic obstructive pulmonary disease, atrial fibrillation
and features of worse HF (higher NYHA class, lower LVEF, lower
systolic blood pressure, longer duration of disease), and also
had higher serum creatinine (Table 1). They were less likely to
be treated with an ACE inhibitor or ARB (Table 1). Baseline
concentrations of all the biomarkers of interest were elevated in
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Adjusted hazard ratio (95% confidence interval) of the primary endpoint and all-cause mortality in relation
to baseline biomarkers, by tertiles and by 1 standard deviation increase in log-transformed biomarkers (n= 1856)
N participants (n HF/CV death,
n all-cause death)
HF hospitalization or CV death All-cause
mortality
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NT-proBNP
T1 610 (119, 124) Ref. Ref.
T2 624 (299, 257) 2.54 (2.04–3.17) 1.84 (1.47–2.31)
T3 619 (416, 388) 3.96 (3.16–4.98) 2.98 (2.38–3.74)
per 1 SD 1853 (834, 769) 1.91(1.74–2.10)
P< 0.001
1.80 (1.63–1.99)
P< 0.001
Troponin T
T1 618 (141, 127) Ref. Ref.
T2 621 (288, 256) 2.06 (1.66–2.55) 1.90 (1.51–2.38)
T3 614 (405, 386) 3.09 (2.47–3.88) 3.10 (2.45–3.93)
per 1 SD 1853 (834, 769) 1.60 (1.48–1.73)
P< 0.001
1.61 (1.48–1.76)
P< 0.001
MR-proADM
T1 628 (182, 157) Ref. Ref.
T2 620 (269, 251) 1.30 (1.07–1.59) 1.40 (1.13–1.73)
T3 605 (383, 361) 2.28 (1.83–2.84) 2.49 (1.96–3.15)
per 1 SD 1853 (834, 769) 1.53 (1.39–1.68)
P< 0.001
1.63(1.47–1.80)
P< 0.001
Copeptin
T1 619 (187, 175) Ref. Ref.
T2 619 (282, 249) 1.46 (1.2–1.76) 1.42 (1.16–1.73)
T3 615 (365, 345) 1.66 (1.35–2.04) 1.78 (1.44–2.20)
per 1 SD 1853 (834, 769) 1.25 (1.15–1.36)
P< 0.001
1.31 (1.19–1.43)
P< 0.001
Cystatin C
T1 633 (188, 169) Ref. Ref.
T2 613 (278, 253) 1.36 (1.12–1.66) 1.28 (1.04–1.57)
T3 607 (368, 347) 1.92 (1.55–2.37) 1.90 (1.52–2.37)
per 1 SD 1853 (834, 769) 1.36 (1.23–1.50)
P< 0.001
1.41 (1.27–1.56)
P< 0.001
CRP
T1 621 (228, 210) Ref. Ref.
T2 614 (268, 245) 1.21 (1.01–1.44) 1.23 (1.02–1.48)
T3 618 (338, 314) 1.51 (1.27–1.80) 1.58 (1.32–1.90)
per 1 SD 1853 (834, 769) 1.17 (1.09–1.25)
P< 0.001
1.19 (1.1–1.28)
P< 0.001
CRP, C-reactive protein; CV, cardiovascular; HF, heart failure; MR-proADM, mid-regional pro-adrenomedullin; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SD,
standard deviation.
Model: adjusting for region, age, sex, race, body mass index, smoking, systolic and diastolic blood pressure, diabetes, chronic obstructive pulmonary disease, New York Heart
Association class, left ventricular ejection fraction, time since diagnosis, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, beta-blocker use, creatinine,
HF hospitalization within last 6months, HF aetiology, stroke, atrial fibrillation/flutter, heart rate.
those who experienced the composite HF event, and in particular
there was an approximate three-fold difference in circulating levels
of NT-proBNP (median 3067 vs. 1027, P< 0.001) (Table 1). Crude
associations were similar for the all-cause mortality endpoint
(supplementary material online, Table S8).
Association between biomarker
concentrations and incident events
The unadjusted Kaplan–Meier curves (Figure 1) showed that the
risk of the composite outcome was higher in patients with higher
levels of each biomarker (log-rank P< 0.001 for all).
In the Cox regression analysis, after adjusting for other risk fac-
tors in the clinical model, NT-proBNP was still strongly associated ..
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. with risk of the composite endpoint both as a continuous variable
and by tertiles of the distribution. Patients in the highest tertile of
the NT-proBNP distribution had an approximately four-fold higher
risk of the composite outcome compared to those in the lowest
tertile (Table 2). For other biomarkers, the higher risk in the top
tertile of the distribution ranged between 1.5-fold for hsCRP and
three-fold for hsTnT (Table 2). A combination of NT-proBNP and
hsTnT gave the strongest risk prediction compared to combina-
tions of other markers and after adjustment, i.e., those in the top
tertile for both NT-proBNP and hsTnT were at 5.3-fold higher risk
compared to those in the lowest tertile of the distribution for both
biomarkers (Figure 2).
The association between higher concentrations of all biomarkers
and risk of all-cause mortality was similar to their prediction of the
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Association of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT) with primary
outcome by tertiles of the distribution of each biomarker, after adjustment for classical risk factors (model as in Table 2).
composite cardiovascular death endpoint. Again, NT-proBNP and
hsTnT were the strongest predictors (Table 2).
Study treatment did not modify the relationship between base-
line biomarker concentrations and outcomes (data not shown).
Incremental predictive information from
biomarkers individually and in
combination
The basic clinical risk-prediction model for the composite end-
point yielded a c-index of 0.687. Each biomarker improved
discrimination when added individually to the clinical model.
When added to the basic model one at a time, NT-proBNP
caused the largest increase in c-index for a single biomarker
(+0.045, P< 0.001), followed by hsTnT (+0.028, P< 0.001),
MR-proADM (+0.017, P< 0.001), cystatin C (+0.01, P< 0.001),
copeptin (+0.008, P< 0.001), and hsCRP (+0.005, P= 0.056)
(Table 3). When NT-proBNP was included in the basic risk model,
none of the other biomarkers improved discrimination further.
However, hsTnT added to NT-proBNP improved NRI. Adding
NT-proBNP to the basic clinical model (+62.3%, P< 0.001)
improved classification of both cases and controls, and addition
of hsTnT further enhanced the NRI (+33.1%, P= 0.004). Adding
other biomarkers made no further improvements.
Patterns for prediction of all-cause mortality were broadly
similar. All biomarkers (except hsCRP) improved discrimination
individually. NT-proBNP improved discrimination and NRI most ..
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. strongly, and only addition of hsTnT resulted in an improvement
in NRI (Table 4).
Discussion
In this analysis, we evaluated four emerging biomarkers in addition
to NT-proBNP and hsTnT in one of the largest studies of chronic
HF patients to date. Although all biomarkers improved risk stratifi-
cation when added to the basic clinical model, NT-proBNP outper-
formed all the other biomarkers in improving model discrimination.
Moreover, apart from hsTnT, none of the other biomarkers
improved model discrimination when added to NT-proBNP.
Several established risk models in HF, based on routinely col-
lected clinical data, perform reasonably effectively.33,34 In recent
years, there has been an explosion of reports of new biomark-
ers in HF, many of which individually predict adverse outcomes
in HF.2–25,35 However, since both NT-proBNP and high-sensitivity
troponins are available as standardized assays in most countries and
are routinely used in the diagnostic work-up of HF and myocar-
dial infarction, these findings have important implications for usual
clinical practice.
Conceptually, a multimarker model is attractive in HF because
an appropriate selection of biomarkers should better reflect the
complex pathophysiology of this syndrome. While our biomarker
panel reflected neurohumoral pathways (copeptin, MR-proADM),
renal function (cystatin C) and inflammation (hsCRP), these
pathways may offer redundant clinical information, and other
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 C-index and continuous net reclassification index for heart failure hospitalization or cardiovascular death
using classical risk markers plus biomarkers (continuous) in those with complete data (n= 1853, n events 834)
Biomarker C-index (95% CI) P-value Net reclassification index
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Classical markers Classical+NT-proBNP Group Classical markers Classical+NT-proBNP
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Comparator 0.687 0.732 – – –
(0.668–0.706) (0.714–0.751)
NT-proBNP 0.732 – Cases 28.9% –
(0.714–0.751) Non-case 33.3% –
P< 0.001 Overall 62.3%, P< 0.001 –
Troponin T 0.715 0.739 Cases 17.1% 9.8%
(0.697–0.734) (0.723–0.756) Non-case 35.8% 23.3%
P< 0.001 P= 0.274 Overall 52.9%, P< 0.001 33.1%, P= 0.004
MR-proADM 0.704 0.735 Cases 21.8% 11.5%
(0.685–0.723) (0.718–0.751) Non-case 24.5% 8.2%
P< 0.001 P= 0.645 Overall 46.3%, P< 0.001 19.7%, P= 0.132
Copeptin 0.695 0.735 Cases 13.5% 10.9%
(0.677–0.714) (0.718–0.752) Non-case 6.9% –3.1%
P< 0.001 P= 0.617 Overall 20.4%, P= 0.034 7.8%, P= 0.36
Cystatin C 0.697 0.734 Cases 17.1% 9.9%
(0.679–0.711) (0.718–0.752) Non-case 8.2% –8.2%
P< 0.001 P= 0.679 Overall 25.3%, P= 0.006 1.7%, P= 0.821
CRP 0.692 0.734 Cases 6.5% 4.8%
(0.673–0.711) (0.718–0.751) Non-case 5.7% –4.4%
P= 0.056 P= 0.663 Overall 12.2%, P= 0.158 0.4%, P= 0.99
All biomarkers 0.738 0.738 Cases 29.1% 11.9%
(0.722–0.755) (0.722–0.755) Non-case 40.9% 19.5%
P< 0.001 P= 0.332 Overall 70%, P< 0.001 31.4%, P= 0.008
CI, confidence interval; CRP, C-reactive protein; MR-proADM, mid-regional pro-adrenomedullin; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Model: adjusting for region, age, sex, race, body mass index, smoking, systolic and diastolic blood pressure, diabetes, chronic obstructive pulmonary disease, New York Heart
Association class, left ventricular ejection fraction, time since diagnosis, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, beta-blocker use, creatinine,
heart failure hospitalization within last 6months, heart failure aetiology, stroke, atrial fibrillation/flutter, heart rate.
potentially important pathophysiological processes such as matrix
remodelling and oxidative stress were not encompassed by our
panel. Moreover, although hsCRP is a reliable marker of inflam-
mation, it may not capture information from all relevant upstream
inflammatory processes in vascular and myocardial diseases.
Therefore, we cannot rule out that more specific inflammatory
markers or alternative biomarkers such as ST2, galectin-3 and
urinary isoprostanes, might have been of additional value. How-
ever, our data suggest that novel biomarkers even moderately
correlated with NT-proBNP and hsTnT are unlikely to provide
meaningful additional risk prediction. Moreover, although our panel
of biomarkers could reflect several pathogenic pathways involved
in the development of HF, it must be recognized that it is not
always clear what pathophysiological mechanism or mechanisms
lead to increased levels of a particular biomarker and it may be
overly simplistic to categorize individual biomarkers in HFrEF in
this way. As such, our data suggest that multimarker approaches
to HF risk stratification are only likely to be worthwhile where
the biomarkers included provide information about pathways
distinct from that provided by natriuretic peptides or troponins.
This is no small consideration; troponins and natriuretic peptides
might largely ‘capture’ information from not only cardiac, but also,
neurohumoral, renal, and inflammatory pathways (as demonstrated ..
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.. by their strong inter-associations), which is partly what makes them
effective biomarkers in risk prediction in a range of populations.
Our study has several limitations. We used a clinical trial cohort,
therefore although the patients are more homogeneous than in
unselected cohorts, as such the data may not be generalizable to
other chronic HF cohorts. There are some regional differences
in patient characteristics, but we adjusted for region in our Cox
models. The majority of our patients had relatively advanced
HFrEF, although it is in this group that prognostication may be
most relevant. Our patients also had anaemia, although this was
mild (median haemoglobin 112 g/dL) and anaemia is common
in HFrEF, especially in more advanced cases. Despite this, our
findings are broadly in line with, and expand on, recently published
data from an unselected cohort of HF patients.35 The narrow
range of haemoglobin concentrations among participants precludes
meaningful study of the way haemoglobin level might modify the
association between other biomarkers and outcomes. The study
focuses on a single baseline measure of biomarkers at an arbitrary
point in an established chronic disease (i.e. at study recruitment);
HFrEF patients may often have clinical blood tests during acute
episodes, which is a different setting.
In conclusion, the established biomarker NT-proBNP offered
greatest prognostic utility for adverse outcome in these chronic
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Table 4 C-index and continuous net reclassification index for all-cause death using classical risk markers plus
biomarkers (continuous) in those with complete data (n= 1853, n events 769)
Biomarker C-index (95% CI) P-value Net reclassification index
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Classical markers Classical+NT-proBNP Group Classical markers Classical+NT-proBNP
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Comparator 0.669 0.713 – – –
(0.651–0.688) (0.694–0.732)
NT-proBNP 0.713 – Cases 23.7% –
(0.694–0.732) Non-case 22.6% –
P= 0.002 Overall 46.3%, P< 0.001 –
Troponin T 0.699 0.721 Cases 14.8% 6.3%
(0.680–0.718) (0.704–0.738) Non-case 31.7% 20.6%
P= 0.002 P= 0.196 Overall 46.5%, P< 0.001 26.9%, P= 0.01
MR-proADM 0.687 0.714 Cases 18.0% 9.5%
(0.668–0.706) (0.695–0.731) Non-case 24.6% 6.5%
P= 0.002 P= 0.890 Overall 42.6%, P< 0.001 16%, P= 0.13
Copeptin 0.676 0.715 Cases 12.8% 11.2%
(0.658–0.695) (0.697–0.732) Non-case 6.5% –2.5%
P= 0.014 P= 0.740 Overall 19.3%, P= 0.036 8.7%, P= 0.346
Cystatin C 0.679 0.715 Cases 18.7% 10.7%
(0.661–0.698) (0.698–0.732) Non-case 4.5% –10.6%
P= 0.002 P= 0.726 Overall 23.2%, P= 0.006 0.2%, P= 0.635
CRP 0.673 0.714 Cases 7.3% 5.7%
(0.654–0.692) (0.696–0.732) Non-case 6.5% –5.5%
P= 0.160 P= 0.778 Overall 13.8%, P= 0.1 0.1%, P= 0.783
All biomarkers 0.719 0.719 Cases 24.1% 11.7%
(0.701–0.737) (0.701–0.737) Non-case 36.7% 15.6%
P= 0.002 P= 0.306 Overall 60.7%, P< 0.001 27.2%, P< 0.001
CI, confidence interval; CRP, C-reactive protein; MR-proADM, mid-regional pro-adrenomedullin; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Model: adjusting for region, age, sex, race, body mass index, smoking, systolic and diastolic blood pressure, diabetes, chronic obstructive pulmonary disease, New York Heart
Association class, left ventricular ejection fraction, time since diagnosis, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, beta-blocker use, creatinine,
heart failure hospitalization within last 6months, heart failure aetiology, stroke, atrial fibrillation/flutter, heart rate.
HFrEF patients with moderate anaemia. Additional neurohumoral,
renal, and inflammatory biomarkers did not predict adverse out-
come as strongly, and did not add to a basic clinical prediction
model which included NT-proBNP, although incremental informa-
tion was added by hsTnT. These data strongly suggest that, given
their increasing availability and standardized methods for detection
in biochemistry departments, future studies in HFrEF must include
both NT-proBNP and high-sensitivity troponin as benchmarks
beyond which other biomarkers, and panels of biomarkers, need
to be tested. More work is now also needed to examine potential
roles of NT-proBNP and/or hsTnT in biomarker-guided therapy
in HFrEF.
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